Cross-Sector entity
Revlimid is most often covered alongside AstraZeneca, which appears in 3 of these 3 stories. The clearest coverage concentration is acquisition: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention Revlimid, all published on August 2, 2026.
3 verified stories tracked
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Revlimid is most often covered alongside AstraZeneca, which appears in 3 of these 3 stories. The clearest coverage concentration is acquisition: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention Revlimid, all published on August 2, 2026. Each carries 2 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Revlimid. Shared-story counts are live from our verified record — not editorial picks.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
The speculative $400 billion merger would rank among the largest ever, offering BMS stockholders an exit from patent headwinds and giving AZN a US listing boost. However, financing structure and antitrust hurdles present major risks.
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
